Our current medicinal chemistry programme against the causative agents of malaria, tuberculosis and helminth infections on one hand, and cardiovascular disease on the other, has five main objectives:

  1. To develop target-directed inhibitors
  2. To progress hits from target- and phenotypic whole cell-based high throughput screening campaigns to deliver leads suitable for optimization and ultimately candidate selection
  3. To generate diversity in complex natural products through semi-synthesis and use of biotransformation.
  4. To employ biotransformation in the generation and characterization of pharmacologically active and potentially toxic reactive metabolites of drugs and drug leads
  5. To repurpose/reposition and rescue clinical compounds
  6. KC’s earlier work included asymmetric synthesis utilizing sulfur and organolanthanide chemistry as well as the total synthesis of natural and designed biologically relevant molecules.

Comments on this entry are closed.